Abstract-Hypertension, which is a risk factor of heart failure, provokes adaptive changes at the vasculature and cardiac levels. Notch3 signaling plays an important role in resistance arteries by controlling the maturation of vascular smooth muscle cells. Notch3 deletion is protective in pulmonary hypertension while deleterious in arterial hypertension. Although this latter phenotype was attributed to renal and cardiac alterations, the underlying mechanisms remained unknown. To investigate the role of Notch3 signaling in the cardiac adaptation to hypertension, we used mice with either constitutive Notch3 or smooth muscle cell-specific conditional RBPJκ knockout. At baseline, both genotypes exhibited a cardiac arteriolar rarefaction associated with oxidative stress. In response to angiotensin II-induced hypertension, the heart of Notch3 knockout and SM-RBPJκ knockout mice did not adapt to pressure overload and developed heart failure, which could lead to an early and fatal acute decompensation of heart failure. This cardiac maladaptation was characterized by an absence of media hypertrophy of the media arteries, the transition of smooth muscle cells toward a synthetic phenotype, and an alteration of angiogenic pathways. A subset of mice exhibited an early fatal acute decompensated heart failure, in which the same alterations were observed, although in a more rapid timeframe. Altogether, these observations indicate that Notch3 plays a major role in coronary adaptation to pressure overload. These data also show that the hypertrophy of coronary arterial media on pressure overload is mandatory to initially maintain a normal cardiac function and is regulated by the Notch3/RBPJκ pathway. (Hypertension. 2016;68:392-400.
H eart failure (HF) is a leading cause of mortality worldwide. HF is defined as the inability of the heart to provide sufficient blood flow to the rest of the organism. The contractile dysfunction observed in HF can be due to either an intrinsic alteration of cardiomyocyte function (eg, alteration of calcium homeostasis or contractile proteins, etc) or to modifications of the microenvironment that limits the input in oxygen and nutrients to cardiomyocytes. 1 Hypertension is a major risk factor for the development of HF. During the course of hypertension, the cardiac hypertrophy and later cardiac fibrosis develop to adapt to pressure overload. 2 In parallel, the media of the artery also hypertrophies to face the increase in pressure and perivascular fibrisos develops, which also contributes to the sustainment of hypertension. 3, 4 The cardiac vasculature plays a major role in hypertension because it needs to adapt to maintain sufficient metabolic input to cardiomyocytes. Consequently, the discoordination between cardiomyocyte hypertrophy and angiogenesis contributes to the progression from adaptive cardiac hypertrophy to HF. 5 However, structural alteration of cardiac microvasculature is not specific to hypertension because microvascular rarefaction and decrease in coronary reserve are commonly associated with idiopathic cardiomyopathies. 6, 7 However, the kinetics of cardiac microvasculature rarefaction, hence its role in the establishment and progression of HF, remains unclear.
Notch receptors are evolutionarily conserved membranetethered transcription factors that regulate cell-cell interactions and mediate cell fate decisions. 8 In mammals, Notch signaling is initiated by the binding of ligand of the Jagged/ Delta-like family to the Notch receptors, which undergo sequential proteolytic cleavages, leading to the nuclear translocation of the Notch intracellular domain. Once in the nucleus, the Notch intracellular domain converts the transcriptional repressor recombination signal-binding protein immunoglobulin κ-J region (RBPJκ) into a transcriptional activator 9 and initiates the transcription of Notch target genes, most of which belong to the hairy enhancer of split (HES) and hairy enhancer of split-related (HEY) gene families. Of note, it has been proposed an alternative noncanonical Notch signaling pathway, whereby Notch intracellular domain transcriptional activity is not mediated through RBPJκ but through the association with other transcriptional regulators. Of the 4 Notch receptors present in mammals, Notch3 is predominantly expressed in the vascular smooth muscle cells (VSMCs) of distal arteries in postnatal period, 10 where it plays a role in the differentiation and maturation of small arterial vessels. 9, 10 Consequently, Notch3 was shown to be involved in the vascular tone of cerebral, tail, 11 and kidney 12 arteries in mouse. In human, dominant-negative mutations of NOTCH3 are responsible for cerebral arteriopathy known as Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarctions and Leukoencephalopathy (CADASIL 13 ) that leads to dementia and death, although a recent work also reported alterations of the coronary microvasculature. 14 Although NOTCH3 loss of function does not lead to CADASIL, 15 it was recently shown to be involved in the context of monocrotaline-induced pulmonary 16 and angiotensin II (angII)-induced systemic hypertension, 12 although with opposite outcome: in the former loss of Notch3 signaling was protective, while in the latter it was associated with a higher mortality that was attributed to renal and cardiac alterations through an unknown mechanism.
In this study, we investigated the impact of the congenital or conditional loss of Notch3 signaling on cardiac adaptation to hypertension. Results clearly show that the absence of Notch3-RBPJκ pathway in VSMCs led to the development of HF in response to pressure overload, with alterations of the cardiac vasculature being a direct causal factor.
Materials and Methods
Materials and Methods are described in detail in the online-only Data Supplement.
Experimental Design
Experimentations were conducted in agreement with the standards of animal care (National Institutes of Health Guide for the Care and Use of Laboratory Animals). Animal work was approved by the French National Committee of Ethic Reflexion on Animal Experimentation (CNREEA number, 09; 2010-12-01 and 2014-10-03). Animals were bred in the local animal facility with free access to water and food.
Three-to 4-month-old male mice with Notch3 deletion (Notch3 −/− ) in a C57Bl/6J background, 17 RBPJκ flox/flox , SM-myosin heavy chainCreERT2 on a mixed C57BL/6J x 129/sv strain, and respective littermate controls were used. SM-RBPJκ −/− animals were generated by mating mice harboring a conditional allele of RBPJκ (RBPJκ flox ) 18 with a tamoxifen-inducible CreER driver mouse line SM-myosin heavy chain-CreERT2, 19 which expresses the CreER recombinase under the control of the VSMC-specific SM-myosin heavy chain promoter. The excision was induced at postnatal week 4 by intraperitoneal injection of tamoxifen (1 mg/d for 5 days) or vehicle (oil) as controls.
AngII-Induced Hypertension Model
After ketamine (90 mg/kg)-xylazin (5 mg/kg) anesthesia, mice were implanted subcutaneously with osmotic mini-pumps (Model 2004, Alzet, Charles River, France) that delivered 1 μg/kg per minute of angII (Sigma Aldrich, France) or saline solution for 4 weeks. Animals were fed with a 5% salt diet as previously described.
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Statistical Analysis
Analyses were performed using the Prism 6 software. Results are expressed as mean±SEM or fold increase, as appropriate. Genotypephenotype interactions were studied by 2-way analysis of variance. Multiple comparisons were performed with 1-way analysis of variance followed by post hoc test with Bonferroni correction. Categorical data were analyzed using exact χ 2 test. A P<0.05 was considered statistically significant.
Results
VSMC Impairment in Notch3 Signaling Promotes HF Secondary to Hypertension
At baseline, Notch3 −/− mice exhibited a cardiac hypertrophy (heart weight/tibia length) when compared with wild-type (WT) animals (P<0.0001), although echocardiographic parameters and systolic blood pressure were similar (Table 1) . After 4 weeks of angII infusion, WT exhibited the typical symptoms of hypertension: elevated blood pressure and cardiac hypertrophy with preserved fractional shortening. Of note, few WT animals died because of aortic dissection or aneurysm rupture, commonly observed in C57Bl/6J genetic background. 20, 21 Notch3 −/− mice also had hypertension but at lesser extent than WT animals (Table 1 ; P<0.001).
In marked contrast, Notch3
−/− +angII mice exhibited an exacerbated cardiac hypertrophy (+28% versus Notch3 −/− ), which was higher than in WT+angII animals (+30%; P<0.001), a cardiac dilatation, and a rapid and sustained decrease in fractional shortening (Table 1) . Together with the increase in cardiac stress markers (Table S2 in the online-only Data Supplement), these data indicate that Notch3 −/− mice developed HF with systolic dysfunction, in response to hypertension. Of note, mortality was earlier and higher in Notch3 −/− +angII mice than in WT+angII animals, as already observed, 12 and was not associated with aortic dissection or aneurysm rupture as in WT mice.
To rule out this phenotype as a result of developmental defect, we tested the conditional invalidation of Notch3 signaling in adult mice. Because Notch3 conditional allele is not available, we therefore selectively deleted the RBPJκ gene specifically in the VSMCs in adult mice, 22 SM-RBPJκ −/− ( Figure S1 ). At baseline, SM-RBPJκ −/− mice did not exhibit any cardiac hypertrophy contrary to Notch3 −/− animals. After receiving angII for 4 weeks, SM-RBPJκ −/− phenocopied Notch3 −/− animals, that is, decrease in fractional shortening, cardiac dilatation, although blood pressure was similar to controls ( Table 2) . Taken together, these data strongly suggest that baseline cardiac hypertrophy in Notch3 −/− results in part from the long-term loss of Notch3 signaling or from a role of Notch3 during development and that the short-term loss of Notch3 signaling in VSMCs in adult is sufficient to promote HF secondary to angII-induced hypertension.
arteries appeared similar in Notch3 −/− , SM-RBPJκ −/− , WT, and control animals ( Figure 1A ; Figure S3A ). After 4 weeks of angII infusion, the media-to-lumen ratio was lower in Notch3 −/− and SM-RBPJκ −/− animals, compared with their respective hypertensive controls ( Figure 1B) , suggesting a lack of media hypertrophy in the absence of Notch3 signaling. Media hypertrophy was not accompanied with VSMC proliferation, as illustrated by the absence of Ki67 label ( Figure S2A ). Furthermore, 30% of the arteries of Notch3 −/− +angII mice were positive to the cleaved caspase 3 staining, a marker of apoptosis activation ( Figure S2B) . Additionally, the VSMCs of Notch3 −/− and SM-RBPJκ −/− animals showed a decrease in F-actin (VSMC-to-cardiomyocyte optical density difference; Figure 1C ) and Acta2 mRNA levels (Table S2 and Figure  S3B ) and an increase in fibronectin with extra-domain A (fibronectin-EDA) ( Figure 1A ; Figure S3A ). This alteration was also found in a model of WT+angII mice infused by Notch3 antisens oligonucleotides ( Figure S4 ), confirming the predominant role of Notch3 in this process. Altogether, these cellular features strongly suggested a transition from contractile to synthetic phenotype of VSMCs in Notch3 signaling-defective animals. Of note, Notch3 −/− mice had a lower level of F-actin content in the VSMCs at baseline compared with WT and SM-RBPJκ −/− ; F-actin decrease in VSMCs was aggravated after angII-induced hypertension.
At the microvasculature level, Notch3
−/− and SM-RBPJκ −/− mice exhibited a lower arteriolar density at baseline compared with WT and control mice ( Figure 2A and 2B); arteriole density was not affected by angII and remained low. In contrast, capillary density was similar in all genotypes at baseline, but was markedly lower in Notch3 −/− and SM-RBPJκ −/− mice after angII infusion compared with WT/control+AngII mice (Figure 2A and 2C) . We therefore investigated angiogenic pathway that could account for such vascular alterations. We observed in Notch3 −/− and SM-RBPJκ −/− mice subjected to angII a lower expression in vascular endothelial growth factor A (VEGFA) and VEGF receptor 2 (VEGFR) proteins (Figure 2D-2F; Table S2 ). Altogether, these data suggest that the inability of the vasculature to adapt to pressure overload in the absence of Notch3 signaling is associated with a decrease in angiogenic pathway and a synthetic VSMC phenotype.
Long-Term Impairment in Notch3 Signaling Promotes Cardiac Remodeling in Hypertensive Mice
One immediate consequence of capillary rarefaction is the imbalance between cardiomyocyte needs and supplies, which usually results in oxidative stress, inflammation, and fibrosis. In both Notch3
−/− and SM-RBPJκ −/− mice, the production of superoxide anions measured in situ by dihydroethidium staining was higher than in controls, when subjected to angII ( Figure 3B and 3C). However, dihydroethidium staining was already higher at baseline in both genetic background compared with their respective controls, suggesting that the initial loss of Notch3 signaling rather than hypertension was responsible.
Although the production of superoxide anions was similar in both Notch3 −/− and SM-RBPJκ −/− groups after angII infusion, all the other parameters we investigated were different between these 2 models. The oxidative damage of cardiac proteins in Notch3 −/− +angII mice ( Figure 3D ) could be associated with an increase in Nox2 transcript level ( Figure 3A) . Furthermore, the myocardium of Notch3 −/− +angII was infiltrated with activated macrophages as illustrated by the presence of CD68-positive cells in cardiac cross-sections ( Figure 3E ), an increase in Spp1, Cd68, Lgals3 (Table S2) , and Galectin-3 ( Figure 3F ) levels. Finally, Notch3 −/− +angII mice exhibited active ongoing cardiac fibrosis compared with WT+angII, as illustrated by the picrosirius red staining ( Figure 3G and 3H) and the increase in Col1a1 and Col1a3 and Fn1 transcripts (Table S2 ). Of note, cardiac fibrosis was already observed in the Notch3 −/− animals at baseline in absence of any signs of inflammation. In contrast, there was neither signs of inflammation nor fibrosis in SM-RBPJκ −/− +angII animals without signs of acute HF (see below), suggesting that the oxidative stress in the hearts resulted from the short-term loss of Notch3 signaling, which led to inflammation and fibrosis later on.
Early Onset Acute Decompensated Heart Failure Is Associated With a Rapid Decrease in Angiogenic Pathway Activity
As mentioned earlier, we observed a peak of mortality around day 6 to 8 after the beginning of angII infusion in both Notch3 −/− (36.7%) and SM-RBPJκ −/− (37.1%) mice. This time point corresponds to the onset of blood pressure plateau, that is, when maximal hypertension is established. Although some animals died of unknown cause, 81.2% of Notch3 −/− +angII and 53.8% of SM-RBPJκ −/− angII animals died from acute decompensated HF (ADHF). To evaluate the role of Notch3 signaling in the early cardiac death in absence of the longterm effect of Notch3 loss of function, we further analyzed SM-RBPJκ −/− animals that developed or not early ADHF, in a context of dilated cardiomyopathy.
At day 6 to 8, all SM-RBPJκ −/− animals exhibited a similar decrease in fractional shortening and a cardiac dilatation. In addition to those symptoms, ADHF animals showed a dramatic decrease in cardiac output, lung congestion that reflects left ventricular dysfunction, and in some cases, anasarca that reflects right ventricular dysfunction ( Figure 4A-4D) . At the molecular level, ADHF was associated with a more intense cardiac oxidative stress associated with Nox2, Lgals3, Col1a1, and Col1a3 mRNA induction ( Figure 4E ; Table S3 ) and a marked decrease in Dll4 transcript levels, which reflects Figure 4H ). Of note, SM-RBPJκ −/− animals that developed ADHF had lower levels of Vegfa transcript and VEGFR2 protein levels compared with controls treated with angII, showing a trend toward a decrease in the components of the VEGFA/VEGFR2 pathway in SM-RBPJκ −/− mice with ADHF ( Figure 4F and 4G). In contrast to what was observed in animals after 4 weeks of angII infusion, there was no alteration of the arteriolar or capillary density, coronary arteries already exhibiting a lack of media hypertrophy in both groups of animals. Altogether, these data indicated that the short-term loss of Notch3 signaling can alter the activity of angiogenic pathway enough to promote fatal ADHF.
Discussion
We show here that the Notch3-RBPJκ signaling pathway is necessary to maintain both the differentiated state of VSMCs and the integrity of the coronary vasculature via the regulation of the VEGFA/VEGFR2/DLL4 pathway, in response to pressure overload. These results are paramount because this is the demonstration of a direct association between a primary alteration of the coronary vasculature and the development of chronic and acute decompensated HF, besides myocardial infarction.
Notch3 loss-of-function was previously shown to be protective in a monocrotaline-induced pulmonary hypertension. 16 In this model, proliferation of VSMCs in small pulmonary arteries leads to a detrimental increase in pulmonary artery resistance, which is dependent on Notch3 signaling. Because Notch3 −/− mice subjected to angII-induced arterial hypertension exhibited a lower increase in blood pressure than their WT counterparts, 12 one may anticipate a similar benefit of the loss of Notch3 signaling in hypertension. To address this question, we analyzed the cardiac adaptation to pressure overload in a combination of a constitutive and a VSMC-specific models of Notch3 signaling impairment. These models allowed us to precise the role of Notch3 signaling in the VSMCs in the context of a hemodynamic challenge and to evaluate the cardiac impact of the short-and long-term loss of Notch3 signaling in the VSMCs.
At baseline, the fact that both Notch3 −/− and VSMCspecific RBPJκ defective mice exhibited a decrease in arteriolar density strongly suggests that Notch3 is not only required during vascularization during development, 23 but also plays a major role in the maintenance of the coronary small arteries. The acquired low arteriolar density in adult SM-RBPJκ −/− animals implies an active and rapid arteriolar regression process in absence of Notch3 signaling in VSMCs, consistent with the proposed role of Notch3 in VSMC survival. 24 VSMCs of the Notch3 −/− coronary arteries exhibited a low F-actin content, which is consistent with the decreased myogenic tone observed in these animals. 11 However, because the F-actin content in VSMCs was unaffected by the invalidation of RBPJκ in adult, the loss of Notch3 signaling does not seem essential to the maintenance of the contractile properties of VSMCs. 25 Importantly, arteriolar rarefaction was associated with oxidative stress in both models, suggesting an immediate impact on cardiac perfusion, although the cardiac function was unaltered. Furthermore, the cardiac hypertrophy and fibrosis in Notch3 −/− mice, in a genetic background usually poorly prone to fibrosis C57Bl/6, 26 strongly suggest that transient variations in hemodynamics under normal living conditions are sufficient to promote a phenotype that is usually observed in hypertensive patients. Altogether, these results indicate that either constitutive or acquired defect in Notch3 signaling induces a functionally silent cardiomyopathy in adult and the incapacity of the coronary tree to adapt to minor hemodynamic variations.
In response to angII-induced hypertension and contrary to Notch3 −/− animals subjected to pulmonary hypertension, both Notch3 −/− and SM-RBPJκ −/− animals developed cardiac systolic dysfunction, as illustrated by the rapid decrease in fractional shortening. Furthermore, a significant proportion of the animals from both backgrounds developed an early and fatal ADHF with typical features of acute cardiac dysfunction, such as decrease in cardiac output, organ congestion, and anasarca. In Notch3 −/− and SM-RBPJκ −/− mice that survived 28 days of angII infusion, the media of coronary arteries was not hypertrophied, VSMCs shifted from a contractile to a synthetic phenotype, and capillary density was reduced in association with a decrease in VEGFR2 signaling. Animals studied after 8 days of angII infusion only exhibited VSMCs with a synthetic phenotype and a lack of media hypertrophy, suggesting that the phenotype observed at day 28 resulted from these initial events. Of note, the vascular phenotype of mice that developed an early fatal ADHF was similar to those which survived throughout the protocol; the only differences being a dramatic and rapid increase in oxidative stress along with a marked decrease in VEGFR2 signaling. Therefore, the early mortality observed was likely because of the acute onset of the same deleterious processes that otherwise progressively developed over 28 days. Altogether, these data indicate that Notch3 signaling plays a critical role in the vasculature adaptation to hemodynamic challenge. Furthermore, these data highlighted that the absence of adaptive media hypertrophy to hypertension is deleterious for the cardiac adaptation to pressure overload and independently from cardiomyocyte hypertrophy. These data parallel those found in cardiomyocytes and strongly suggest that the development of therapeutics that would solely block cardiomyocyte or media hypertrophy without blocking the main cause, that is, pressure overload, will be harmful in some instances. 27 From a clinical standpoint, NOTCH signaling has emerged as a key player in diseases affecting the cardiovascular system. [28] [29] [30] Indeed, JAG1 and NOTCH2 mutations are responsible for the Alagille syndrome, 31, 32 and mutations in the MIB1 gene have been associated with left ventricular noncompaction cardiomyopathy, reviewed in Towbin et al. 33 To date, NOTCH3 mutations have been associated with CADASIL 15 and pulmonary hypertension. 34 The phenotype observed −/− mice strongly suggests that loss-of-function mutations of NOTCH3-different from those identified in CADASIL-could be responsible for cardiomyopathy that would become clinically symptomatic on hemodynamic challenging conditions. Indeed, the phenotype of angII-induced hypertensive Notch3
−/− and SM-RBPJκ −/− animals recapitulates what is observed in patients with an idiopathic dilated cardiomyopathy: alteration of the coronary vasculature and capillary rarefaction, 6 which is strongly related to a decrease in coronary flow reserve. 7 In conclusion, we showed for the first time that the hypertrophy of coronary arterial media on pressure overload is mandatory to initially maintain a normal cardiac function and is regulated by the Notch3/RBPJκ pathway. These observations extend the role of Notch3 in VSMC proliferation observed in vitro 35 and in pulmonary hypertension 16 to that of VSMC survival and maintenance of the contractile phenotype. Finally, this work highlights Notch3 signaling as an important factor to consider in future investigations regarding the molecular mechanisms involved in the vascular adaptation on hemodynamic challenge.
Perspectives
Given the deleterious effect of NOTCH3 activity in the development of pulmonary hypertension, 16 acute kidney disease, 36 and some cancers, 37, 38 antagonists of NOTCH3 signaling have been considered as potential therapy. However, our data challenge the development of such therapeutic approach because the immediate cardiovascular impact could be disastrous similar to the cardiotoxic effects of antiangiogenic drugs, such as bevacizumab and sunitinib used in cancer therapy. 39 • In this study, we showed that besides its role in the differentiation of vascular smooth muscle cells and in the vascular tone, Notch3 signaling is necessary for the vascular adaptation to hypertension. The consequence of Notch3 signaling impairment is a severe dilated cardiomyopathy that can progress to heart failure.
What Is Relevant?
• The hypertrophy of the media in response to hypertension seems to be critical for cardiac adaptation, and Notch3 plays a major role in this process. These data also propose Notch3 mutations as potentially responsible for dilated cardiomyopathies and challenge the therapeutic development targeting the Notch3 pathway.
Summary
We investigate the role of Notch3 signaling pathway during angiotensin II-induced hypertension, in vivo. The Notch3 −/− and SM-RBPJκ −/− hearts did not adapt to hypertension, which led to an early and fatal acute decompensated heart failure. Thus, the hypertrophy of coronary media on hypertension seems mandatory to maintain a cardiac function and is regulated by the canonical Notch3/RBPJκ pathway. 
EXPANDED METHODS
Animal models
In addition to models described in the material and method section, SMMHC-CreERT2 mice were also crossed with Rosa26-Stopfl-LacZ reporter mice 1 to monitor tamoxifen-induced Cre/Lox recombination.
Besides, Notch3 repression was also obtained by antisens Oligonucleotide strategy. Notch3 pathway blockade was achieved by a cocktail of two different sequences of oligonucleotides specifically targeting Notch3 mRNA as previously described. 2 For control groups, we designed a cocktail of two scrambled sequences. To achieve this aim, the antisens or scrambled oligonucleotides were diluted in saline sodium chloride and delivered by osmotic mini-pump for 28 days (1 µM per days) to WT adult male mice as described in method section.
Systolic Blood Pressure and Echocardiography
Systolic blood pressure was measured in vigil mice with a tail-cuff sphygmomanometer (Kent Scientific Corporation, Torrington, USA). Echocardiographic images were acquired using 14-MHz-linear-array transducer with a digital ultrasound system (ACUSSON S3000, Siemens Healthcare, Germany), as previously described. (1:250, Thermo-Fisher Scientific, France) secondary antibodies were used for detection. For polymerized actin detection and superoxide anions, sections were incubated in FITC-labeled phalloidin (0.33 µM in PBS, Sigma-Aldrich, France) or Dihydroethidium (37 µM in PBS, DHE, Sigma-Aldrich, France), respectively for 30 min in a dark humidified chamber. All crosssections were then mounted with Vectashield (Vector laboratories, Clinisciences, France). Collagen fibers were stained using picrosirius red (0.5% in saturated picric acid), dehydrated, mounted in Eukit (CML, France), and observed under polarized light.
Image analysis
All images were acquired on a Leica microscope using identical settings for exposure for each parameter (Leica Microsystems, France). All the measurements were performed blinded for experimental conditions using the IPLab software (BD Biosciences, USA). Coronary VSMC Factin content was expressed as the VSMC-to-cardiomyocyte difference in FITC-phalloidin optical density for each section. 4 The FITC-phalloidin optical density of neighboring cardiomyocytes was used as internal control, to ensure the validity of the measure at the coronary levels (3 sections/heart and 4 mice/group). Superoxide anion production was quantified as the number of DHE-positive pixel normalized to the image area on 4 fields per section, 3 sections per heart, and 4 mice per group, and expressed as percent.
The amount of fibrosis was quantified as the Sirius red-positive area/total ventricular surface ratio on at least 5 fields per section, 3 sections per heart, and at least 5 mice per group. Arteriolar density was quantified as the number of arterioles (x10 magnification), using 8-11 fields per cross-section, 3 cross-sections per heart, and 4 mice per group. Coronary artery remodeling (diameters >20 µm) was evaluated by calculating the media-to-lumen ratio. Capillary density, defined as the capillary-to-cardiomyocyte ratio, was measured as the number of caveolin-1-labelled cells (endothelium) over the number of vinculin-positive cells (cardiomyocyte). A minimum of 4 fields per cross-section, 3 cross-sections per heart, and 4 mice per groups were used.
Gene Expression Analysis
For RT-quantitative PCR analyses, total RNA extraction from the left ventricles, reverse transcription and qPCR were performed as previously described.
5 mRNA data were normalized by the abundance of glyceraldehyde-3-phosphate dehydrogenase (Gapdh) mRNA for each sample with the comparative threshold method 6 and expressed as the relative change compared with the control sample. Primers are listed in Table S1 .
Protein Analysis
Heart tissue was lysed and homogenized in lysis buffer (50 mM Tris HCl pH7.4, 1 mM EDTA, 150 mM NaCl). Cell lysis buffer with 1% Na Deoxycholate and 1% Triton were used for vascular endothelial growth factor receptor 2 (VEGFR2) and protein oxidation detection, respectively. After centrifugation (12000 rpm, 10 min, +4 °C), soluble proteins were quantified by Pierce BCA Protein Assay Kit (ThermoFischer Scientific, France). Supernatants were stored at −80 °C.
Western Blot Analysis
Protein extracts (20 µg) were subjected to SDS-PAGE polyacrylamide gels (Biorad) and transferred to 0.45-μm nitrocellulose membrane. Nitrocellulose blots were blocked and incubated with mouse anti-galectin 3 (1:1000, Thermo Fischer Scientific, France), rabbit anti-VEGFA (1:2000, Millipore, France), rabbit anti-VEGFR2 (1:1000, Cell signaling, Ozyme, France), or rabbit anti-Notch3 (1:1000, Abcam, UK) antibodies overnight at 4 °C. Blots were incubated with sheep anti-mouse (1:5000; GE Healthcare, France) or goat anti-rabbit (1:5000, Sigma-Aldrich, France) horseradish Peroxidase-Linked antibodies for 1 h at room temperature before being incubated with ECL Prime (GE Healthcare, France). Chemiluminescence was detected using a LAS 3000 (Fuji, France) and measured using MultiGauge V2.02 software (Fuji). 
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